gsk201603016k5.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending March 2016
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 
GlaxoSmithKline plc
 
Notification of Transactions of Directors and Persons Discharging Managerial Responsibility or Connected Persons
 
GlaxoSmithKline Share Value Plan
 
Withholding of shares to meet tax liabilities
 
 
The table below sets out changes in the interests of a connected person of a Person Discharging Managerial Responsibility (PDMR) in the American Depositary Shares (ADS) of GlaxoSmithKline plc arising from the withholding of ADSs at a fair market value of $39.14 per ADS (the closing price on 26 February 2016 which was the business day prior to vesting) to meet tax liabilities following the vesting of the award granted in 2013 under the GlaxoSmithKline 2009 Share Value Plan (SVP).
 
Name of PDMR
Name of Connected Person
Number of ADSs withheld to meet tax liabilities following the vesting of a SVP award
Dr M Slaoui*
Dr K Slaoui
1,256
 
*Denotes an Executive Director
 
The Company and the above individual were advised of this transaction on 29 February 2016.
 
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
 
V A Whyte
Company Secretary
 
1 March 2016



 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: 01 March, 2016
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc